Steroid induced osteoporosis: Prevention and treatment;Prévention et traitement de l'ostéoporose cortisonique

Revue de Medecine Interne

Volumn 24, Issue 6, 2003, Pages 384-388

  Roux, C ^a   Orcel, P ^b  

^a Institut Cochin   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Bisphosphonates; Bone densitometry; Corticosteroids; Fractures; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID;

BONE DENSITY; BONE MINERAL; CALCIUM DEFICIENCY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG INDICATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HUMAN; HYPOGONADISM; LONG TERM CARE; OSTEOBLAST; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; RISK FACTOR; VITAMIN D DEFICIENCY;

EID: 0038818493     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(03)00105-X     Document Type: Article

References (31)

1. Khosla S, Lufkin EG, Hodgson SF, Fitzpatrick LA, Melton III LJ. Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994;15:551-5.
2. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999:1061-6.
3. Weistein RS, Jilka RL, Parfit AM, Manologas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 1998;102:274-82.
4. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-74.
5. Weinstein RS, Chen J, Powers CC, Stewart SA, Landes RD, Bellido T, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002;109:1041-8.
6. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-9.
7. Lespessailles E, Siroux V, Poupon S, Andriambelosoa N, Pothnaud L, Harba R, et al. Long-term corticosteroid therapy induces mild changes in trabecular bone texture. J Bone Miner Res 2000;15:747-53.
8. Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 1996;11:676-85.
9. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001;16:97-103.
10. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, et al. Effects of alendronate on bone quality and remodelling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000;15:754-62.
11. Walsh LJ, Wong CA, Pringle M, Tattersfieldk AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Br Med J 1996;313:344-6.
12. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroid and risk of fractures. J Bone Miner Res 2000;15:993-1000.
13. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801-6.
14. Laan RF, Van Riel PL, Van de Putte LB, Van Erning LJ, Van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized controlled study. Ann Intern Med 1993;119:963-8.
15. Peel NFA, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treatment of patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:801-6.
16. Selby PL, Halsey JP, Adams KRH, et al. Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res 2000;15:952-6.
17. Lane NE, Sanchez S, Modin G, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse steroid osteoporosis: results of a randomized clinical trial. J Clin Invest 1998;102:1627-33.
18. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
19. Adachi JA, Saag KG, Delmas PD, Libermann UA, Emkey DE, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. Arthritis Rheum 2001;44:202-11.
20. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999;42:2309-18.
21. Reid DM, Hugues RA, Laan RFJM, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000;15:1006-13.
22. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
23. Eastell R, Devogelaer JP, Peel NFA, Chines AA, Bax DE, Sacco-Gibson N, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporosis Int 2000;11:331-7.
24. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
25. Roux C, Oriente P, Laan R, Hugues RA, Ittner J, Goemaere S, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998;83:1128-33.
26. Adachi JA, Roux C, Geusens P, Pitt PI, Cooper C, Moniz C, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid-induced bone loss. J Rheumatol 2000;27:2424-31.
27. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intra-venous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001;16:104-12.
28. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999;26:1148-57.
29. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002;17:1512-26.
30. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-7.
31. van Staa TP, Leufkens HGM, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001;3:581-8.